METHODS A group of 8 experts on the management of schizophrenia and LAIs met to
evaluate the evidence and to develop a set of recommendations regarding the clinical use …

Background The research goal is to better understand prescriber, patient, and caregiver
perspectives about long-acting injectable (LAI) antipsychotic therapy and how these …

Schizophrenia and related disorders remain major disabling conditions, mainly due to
antipsychotic treatment resistance and to relapses related to antipsychotic nonadherence …

Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs)
should improve medication adherence and reduce relapses in schizophrenia. However …

Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often
regarded with some negativity because of the assumption of punishment, control and …

Aim Results from clinical trials support the use of oral antipsychotics for treatment of early or
first‐episode psychosis in patients with schizophrenia. This paper will review literature on …

Schizophrenia is a serious mental illness that requires continuous and effective long-term
management to reduce symptoms, improve quality of life, and prevent relapse. Oral …

Opinion Statement Schizophrenia is a mostly chronic mental disorder, and symptomatic
relapse is frequently observed. It is often associated with social and/or occupational decline …

Importance of the field: Antipsychotic medications are the cornerstone of treatment in
schizophrenia, and a large body of data confirms the value of ongoing and continuous …

Background Long-acting injectable (LAI) formulations are not widely used in routine practice
even though they offer advantages in terms of relapse prevention. As part of a process to …